{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:00:00Z","timestamp":1793916000681,"version":"4.8.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T00:00:00Z","timestamp":1550448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13045-019-0704-y","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T13:02:56Z","timestamp":1550494976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer"],"prefix":"10.1186","volume":"12","author":[{"given":"Jiang","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruocong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diwei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youguo","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simiao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suna","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yantao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suimin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duanqing","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pentao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuchao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,18]]},"reference":[{"issue":"5","key":"704_CR1","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1158\/1055-9965.EPI-13-1057","volume":"23","author":"P Karimi","year":"2014","unstructured":"Karimi P, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomark Prev. 2014;23(5):700\u201313.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"3","key":"704_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00428-013-1533-y","volume":"464","author":"C Duraes","year":"2014","unstructured":"Duraes C, et al. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch. 2014;464(3):367\u201378.","journal-title":"Virchows Arch"},{"issue":"7","key":"704_CR3","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.3748\/wjg.v20.i7.1635","volume":"20","author":"M Orditura","year":"2014","unstructured":"Orditura M, et al. Treatment of gastric cancer. World J Gastroenterol. 2014;20(7):1635\u201349.","journal-title":"World J Gastroenterol"},{"key":"704_CR4","doi-asserted-by":"crossref","unstructured":"Correction: mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunol Res, 2015. 3(2): p. 217.","DOI":"10.1158\/2326-6066.CIR-15-0007"},{"key":"704_CR5","doi-asserted-by":"publisher","first-page":"2732408","DOI":"10.1155\/2018\/2732408","volume":"2018","author":"H Magalhaes","year":"2018","unstructured":"Magalhaes H, Fontes-Sousa M, Machado M. Immunotherapy in advanced gastric Cancer: an overview of the emerging strategies. Can J Gastroenterol Hepatol. 2018;2018:2732408.","journal-title":"Can J Gastroenterol Hepatol"},{"key":"704_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1756-8722-5-31","volume":"5","author":"L Liu","year":"2012","unstructured":"Liu L, Wu N, Li J. Novel targeted agents for gastric cancer. J Hematol Oncol. 2012;5:31.","journal-title":"J Hematol Oncol"},{"issue":"9742","key":"704_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang Y-J, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"issue":"5","key":"704_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/apm.12359","volume":"123","author":"A Thiel","year":"2015","unstructured":"Thiel A, Ristimaki A. Targeted therapy in gastric cancer. APMIS. 2015;123(5):365\u201372.","journal-title":"APMIS"},{"issue":"3","key":"704_CR9","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3892\/or.2015.4528","volume":"35","author":"DD Yuan","year":"2016","unstructured":"Yuan DD, et al. Targeted therapy for gastric cancer: current status and future directions (review). Oncol Rep. 2016;35(3):1245\u201354.","journal-title":"Oncol Rep"},{"issue":"1","key":"704_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-016-0340-8","volume":"9","author":"J Yu","year":"2016","unstructured":"Yu J, et al. Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis. J Hematol Oncol. 2016;9(1):111.","journal-title":"J Hematol Oncol"},{"issue":"6","key":"704_CR11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","volume":"17","author":"K Muro","year":"2016","unstructured":"Muro K, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. The Lancet Oncology. 2016;17(6):717\u201326.","journal-title":"The Lancet Oncology"},{"key":"704_CR12","doi-asserted-by":"crossref","unstructured":"Fuchs CS, et al. KEYNOTE-059 cohort 1: efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. J Clin Oncol. 2017;35","DOI":"10.1200\/JCO.2017.35.15_suppl.4003"},{"issue":"5","key":"704_CR13","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-09-2870","volume":"16","author":"C Ralph","year":"2010","unstructured":"Ralph C, et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res. 2010;16(5):1662\u201372.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"704_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13045-017-0511-2","volume":"10","author":"J Long","year":"2017","unstructured":"Long J, et al. PD-1\/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. J Hematol Oncol. 2017;10(1):146.","journal-title":"J Hematol Oncol"},{"issue":"6382","key":"704_CR15","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361\u20135.","journal-title":"Science"},{"issue":"12","key":"704_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1251539","volume":"5","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, et al. CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: from bench to bedside. Oncoimmunology. 2016;5(12):e1251539.","journal-title":"Oncoimmunology"},{"issue":"16","key":"704_CR17","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"key":"704_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","volume":"5","author":"C Zhang","year":"2017","unstructured":"Zhang C, et al. Engineering CAR-T cells. Biomark Res. 2017;5:22.","journal-title":"Biomark Res"},{"issue":"1","key":"704_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-017-0444-9","volume":"10","author":"S Yu","year":"2017","unstructured":"Yu S, et al. Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol. 2017;10(1):78.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"704_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13045-017-0535-7","volume":"10","author":"B Liu","year":"2017","unstructured":"Liu B, Song Y, Liu D. Clinical trials of CAR-T cells in China. J Hematol Oncol. 2017;10(1):166.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"704_CR21","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrc.2016.97","volume":"16","author":"AD Fesnak","year":"2016","unstructured":"Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16(9):566\u201381.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"704_CR22","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121(5):1822\u20136.","journal-title":"J Clin Invest"},{"issue":"2","key":"704_CR23","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/mt.2009.210","volume":"18","author":"XS Zhong","year":"2010","unstructured":"Zhong XS, et al. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther. 2010;18(2):413\u201320.","journal-title":"Mol Ther"},{"issue":"13","key":"704_CR24","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/0008-5472.CAN-11-0422","volume":"71","author":"DG Song","year":"2011","unstructured":"Song DG, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011;71(13):4617\u201327.","journal-title":"Cancer Res"},{"issue":"1","key":"704_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/cr.2016.154","volume":"27","author":"LA Johnson","year":"2017","unstructured":"Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. Cell Res. 2017;27(1):38\u201358.","journal-title":"Cell Res"},{"issue":"1","key":"704_CR26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1073\/pnas.93.1.136","volume":"93","author":"K Chang","year":"1996","unstructured":"Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996;93(1):136\u201340.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"704_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3892\/or.2013.2803","volume":"31","author":"T Ito","year":"2014","unstructured":"Ito T, et al. ERC\/mesothelin is expressed in human gastric cancer tissues and cell lines. Oncol Rep. 2014;31(1):27\u201333.","journal-title":"Oncol Rep"},{"key":"704_CR28","doi-asserted-by":"crossref","unstructured":"Sotoudeh M, et al. MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the potent antigenic targets for CAR T cell therapy of gastric adenocarcinoma. J Cell Biochem. 2018;","DOI":"10.1002\/jcb.27776"},{"issue":"2","key":"704_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","volume":"6","author":"A Morello","year":"2016","unstructured":"Morello A, Sadelain M, Adusumilli PS. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov. 2016;6(2):133\u201346.","journal-title":"Cancer Discov"},{"key":"704_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.pharmthera.2016.06.010","volume":"166","author":"GL Beatty","year":"2016","unstructured":"Beatty GL, O'Hara M. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps. Pharmacol Ther. 2016;166:30\u20139.","journal-title":"Pharmacol Ther"},{"key":"704_CR31","doi-asserted-by":"crossref","unstructured":"Watanabe K, et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight. 2018;3(7)","DOI":"10.1172\/jci.insight.99573"},{"issue":"1","key":"704_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","volume":"155","author":"GL Beatty","year":"2018","unstructured":"Beatty GL, et al. Activity of Mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology. 2018;155(1):29\u201332.","journal-title":"Gastroenterology"},{"issue":"2","key":"704_CR33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty GL, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2(2):112\u201320.","journal-title":"Cancer Immunol Res"},{"key":"704_CR34","unstructured":"Zhao, R., et al., DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells OncoImmunology (accepted)."},{"issue":"3","key":"704_CR35","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/leu.2017.249","volume":"32","author":"Y Lai","year":"2018","unstructured":"Lai Y, et al. Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T cells. Leukemia. 2018;32(3):801\u20138.","journal-title":"Leukemia"},{"issue":"5","key":"704_CR36","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3324\/haematol.2014.118612","volume":"100","author":"Y Xiao","year":"2015","unstructured":"Xiao Y, et al. ANGPTL7 regulates the expansion and repopulation of human hematopoietic stem and progenitor cells. Haematologica. 2015;100(5):585\u201394.","journal-title":"Haematologica"},{"issue":"3","key":"704_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1284722","volume":"6","author":"X Wei","year":"2017","unstructured":"Wei X, et al. PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. Oncoimmunology. 2017;6(3):e1284722.","journal-title":"Oncoimmunology"},{"key":"704_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-015-0156-y","volume":"8","author":"W Ye","year":"2015","unstructured":"Ye W, et al. Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments. J Hematol Oncol. 2015;8:59.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"704_CR39","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12(4):237\u201351.","journal-title":"Nat Rev Cancer"},{"key":"704_CR40","first-page":"3850839","volume":"2016","author":"Y Guo","year":"2016","unstructured":"Guo Y, Wang Y, Han W. Chimeric antigen receptor-modified T cells for solid tumors: challenges and prospects. J Immunol Res. 2016;2016:3850839.","journal-title":"J Immunol Res"},{"issue":"22","key":"704_CR41","doi-asserted-by":"publisher","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","volume":"70","author":"Y Zhao","year":"2010","unstructured":"Zhao Y, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010;70(22):9053\u201361.","journal-title":"Cancer Res"},{"issue":"2","key":"704_CR42","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty GL, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. Cancer Immunology Research. 2014;2(2):112\u201320.","journal-title":"Cancer Immunology Research"},{"issue":"5","key":"704_CR43","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2217\/imt.15.15","volume":"7","author":"H Abken","year":"2015","unstructured":"Abken H. Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors. Immunotherapy. 2015;7(5):535\u201344.","journal-title":"Immunotherapy"},{"issue":"2","key":"704_CR44","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/PPO.0000000000000032","volume":"20","author":"S Kakarla","year":"2014","unstructured":"Kakarla S, Gottschalk S. CAR T cells for solid tumors: armed and ready to go? Cancer J. 2014;20(2):151\u20135.","journal-title":"Cancer J"},{"issue":"261","key":"704_CR45","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","volume":"6","author":"PS Adusumilli","year":"2014","unstructured":"Adusumilli PS, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014;6(261):261ra151.","journal-title":"Sci Transl Med"},{"issue":"1","key":"704_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0548-2","volume":"11","author":"J Yu","year":"2018","unstructured":"Yu J, et al. Anti-GD2\/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients. J Hematol Oncol. 2018;11(1):1.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"704_CR47","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jvir.2018.03.001","volume":"29","author":"JC Hardaway","year":"2018","unstructured":"Hardaway JC, et al. Regional infusion of chimeric antigen receptor T cells to overcome barriers for solid tumor immunotherapy. J Vasc Interv Radiol. 2018;29(7):1017\u201321. e1","journal-title":"J Vasc Interv Radiol"},{"issue":"12","key":"704_CR48","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","volume":"5","author":"J Tchou","year":"2017","unstructured":"Tchou J, et al. Safety and efficacy of Intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast Cancer. Cancer Immunol Res. 2017;5(12):1152\u201361.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"704_CR49","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","volume":"24","author":"SJ Priceman","year":"2018","unstructured":"Priceman SJ, et al. Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2(+) breast Cancer metastasis to the brain. Clin Cancer Res. 2018;24(1):95\u2013105.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"704_CR50","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/cgt.2016.14","volume":"23","author":"SC Katz","year":"2016","unstructured":"Katz SC, et al. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. Cancer Gene Ther. 2016;23(5):142\u20138.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"704_CR51","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-018-0568-6","volume":"11","author":"J Li","year":"2018","unstructured":"Li J, et al. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. J Hematol Oncol. 2018;11(1):22.","journal-title":"J Hematol Oncol"},{"key":"704_CR52","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40164-017-0088-z","volume":"6","author":"L Qin","year":"2017","unstructured":"Qin L, Zhao R, Li P. Incorporation of functional elements enhances the antitumor capacity of CAR T cells. Exp Hematol Oncol. 2017;6:28.","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"704_CR53","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/gt.2017.81","volume":"25","author":"Y Huang","year":"2018","unstructured":"Huang Y, et al. Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy. Gene Ther. 2018;25(3):192\u20137.","journal-title":"Gene Ther"},{"issue":"7","key":"704_CR54","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute G, et al. Transgenic expression of IL15 improves antiglioma activity of IL13Ralpha2-CAR T cells but results in antigen loss variants. Cancer Immunol Res. 2017;5(7):571\u201381.","journal-title":"Cancer Immunol Res"},{"issue":"13","key":"704_CR55","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu B, et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 2017;20(13):3025\u201333.","journal-title":"Cell Rep"},{"issue":"22","key":"704_CR56","doi-asserted-by":"publisher","first-page":"6982","DOI":"10.1158\/1078-0432.CCR-17-0867","volume":"23","author":"S Li","year":"2017","unstructured":"Li S, et al. Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors. Clin Cancer Res. 2017;23(22):6982\u201392.","journal-title":"Clin Cancer Res"},{"key":"704_CR57","doi-asserted-by":"crossref","unstructured":"Rafiq S, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;","DOI":"10.1038\/nbt.4195"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-019-0704-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-019-0704-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-019-0704-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T01:21:32Z","timestamp":1662945692000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-019-0704-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,18]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["704"],"URL":"https:\/\/doi.org\/10.1186\/s13045-019-0704-y","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,18]]},"assertion":[{"value":"20 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Human whole peripheral blood mononuclear cells were collected from healthy volunteers in the Department of Hematology, Guangdong General Hospital, Guangzhou, China. Primary gastric tumor tissues and normal gastric tissues were provided by the Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China. Donors who provided primary specimens gave informed consent for the use of their samples for research purposes, and all procedures were approved by the Research Ethics Board of Guangzhou Institutes of Biomedicine and Health (GIBH).All animal experiments were performed at the Laboratory Animal Center of the Guangzhou Institutes of Biomedicine and Health (GIBH), and all procedures were approved by the Animal Welfare Committee of GIBH. NOD-scid-IL2Rg<sup>\u2212\/\u2212<\/sup> (NSI) mice were derived at GIBH. All mice were maintained in specific pathogen-free cages and provided autoclaved food and water. Animal protocols were approved by the institutional animal care and use committee (IACUC).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"18"}}